Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Expects ‘Strong Year’ With ‘First’ EU Spiriva Rival Imminent

Signed Licensing Deal For Tiotropium Bromide In 2018

Executive Summary

Glenmark said it would continue to deliver new respiratory products in Europe moving forward as the Indian firm lines up what it believes will be the first generic version of Boehringer Ingelheim’s Spiriva Handihaler.

You may also be interested in...



Glenmark Launches Tiotropium DPI In Spain

India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets. 

Glenmark Celebrates European Ryaltris Approvals

Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.

Japan’s Sawai Benefits In Domestic Market From Rivals’ Supply Misery

Sawai was strong in Japan and weak in the US in the first financial quarter of its 2022 financial year, as analysts called on the Japanese firm to improve supply capacity as a “crucial first step towards expanding market share.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel